Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Eukaryotic Gene Expression
Импакт фактор: 1.841 5-летний Импакт фактор: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN Печать: 1045-4403
ISSN Онлайн: 2162-6502

Выпуски:
Том 29, 2019 Том 28, 2018 Том 27, 2017 Том 26, 2016 Том 25, 2015 Том 24, 2014 Том 23, 2013 Том 22, 2012 Том 21, 2011 Том 20, 2010 Том 19, 2009 Том 18, 2008 Том 17, 2007 Том 16, 2006 Том 15, 2005 Том 14, 2004 Том 13, 2003 Том 12, 2002 Том 11, 2001 Том 10, 2000 Том 9, 1999 Том 8, 1998 Том 7, 1997 Том 6, 1996 Том 5, 1995 Том 4, 1994

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2018025121
pages 373-384

Interferon-Free Regimen for Hepatitis C: Insight and Management

Muhammad Shareef Masoud
Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Pakistan
Usman Ali Ashfaq
Department of Bioinformatics & Biotechnology, Government College University, 38000 Faisalabad, Pakistan
Hina Khalid
Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Pakistan

Краткое описание

The rapid development of direct-acting antiviral agents (DAA) for hepatitis C virus (HCV) therapy dramatically altered the treatment landscape of this disease. The DAA regimen is associated with various advantages including high sustained virological response (SVR) with minimum side effects and low pill load and specific inhibition of viral replication, which lowers dependence on the host cell. This regimen has substantially replaced conventional (interferon) therapy with high cure rates (> 90%) in most HCV populations. This review provides insight into clinical studies of NS3/4A protease inhibitors, NS5B viral polymerase inhibitor (nucleotide and non-nucleotide), and NS5A inhibitors, alone and in combination.

Ключевые слова: NS3 protease inhibitor, NS5B inhibitor, HCV

Articles with similar content:

Immune Responses Against Persistent Viral Infections: Possible Avenues for Immunotherapeutic Interventions
Critical Reviews™ in Immunology, Vol.28, 2008, issue 2
Edward J. Usherwood, Michael J. Molloy, Shinichiro Fuse
Mechanism of Hepatitis C Virus−Induced Diabetes Mellitus
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Usman Ali Ashfaq, Hina Khalid
Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway
Forum on Immunopathological Diseases and Therapeutics, Vol.6, 2015, issue 1-2
Haydn T Kissick, Eunseon Ahn, Junghwa Lee, Rafi Ahmed
Immunotherapy of Colon Cancer Using Chimeric mAb 31.1
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Tommy Wang, Myron Arlen, Al Tsang
Recent Progress in Polymeric Gene Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.20, 2003, issue 4
Sanjeev Kumar Mendiratta, Khursheed Anwer, B. G. Rhee